"THLD's Phase 3 soft tissue sarcoma trial is likely to play out with topline results by Q3/15 or Q4/15." (1/27/15) Threshold Pharmaceuticals Inc. - The Life Sciences Report Interview with George Zavoico Moreá>
"If all goes well, CUR's NSI-189 product will move into Phase 2 development in Q2/15, so that is a good advancement opportunity." (1/22/15) Neuralstem Inc. - The Life Sciences Report Interview with Edward Stopke Moreá>
"ATHX completed enrollment in its Phase 2 stroke study before the new year, so the first 90-day results will emerge in Q1/15E." (1/22/15) Athersys Inc. - The Life Sciences Report Interview with Edward Stopke Moreá>
Some companies with expected catalysts
Johnson & Johnson Merck & Co. Neuralstem Inc.
Top Investors and Analysts Use this Exclusive Report to Anticipate the Prospects of Medical and Biotech Stocks.
Now you can, too!
Access to the BioMed Tracker Quarterly Outlook Reports usually costs $2,000. For a limited time you can get access to the Report for FREE.
Biomedical stocks can soar depending on key catalysts and outcomes, such as FDA approval, regulatory changes, and clinical studies. The more accurately you can anticipate the results, the higher your profits.
We know that portfolio managers and analysts will pay big bucks for top-flight investment research. And for many investors and analysts the ultimate interactive biotech & pharmaceutical investment tool is the BioMedTracker Report from Sagient Research:
- The BioMedTracker Outlook report is sorted by catalyst type, date and company, giving you quick, sortable access to exclusive information.
- The Report usually costs $2,000 per year.
Right now, for a limited time, Sagient is offering free access to the current BioMedTracker Report to readers of Streetwise Reports.
"The vote of confidence CTH has received from The Michael J. Fox Foundation is very advantageous." (1/8/15) Cynapsus Therapeutics Inc. - The Life Sciences Report Interview with Daniel Pearlstein Moreá>
"The new year holds a great deal of promise for the field of regenerative medicine, with companies like NEO at the forefront." (12/30/14) NeoStem Inc. - The Life Sciences Report Interview with Steve Brozak Moreá>